Jan. 17 at 9:29 AM
$CRBU The stock feels abandoned right now but nothing fundamental has broken. The market is simply waiting for clarity. The key things shareholders are looking for are a clear funding plan, a defined timeline for CB011 dose expansion, and confirmation of next clinical milestones. The Phase 1 data is already in hand and it was strong. Until management fills in those blanks sentiment will stay weak, but once guidance comes the narrative can shift quickly. This is a waiting game, not a failed story.
